The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2804 participants.

Also called NCT07381803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,804 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07381803
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07381803. Randomized; triple masking; primary purpose treatment. Start 2025-01-27 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
Condition
Zhejiang University
Intervention (Drug)
Fexofenadine 60 Mg Oral Tablet
Intervention (Drug)
Placebo
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07381803
Content hash
11bceffd667ad7680d3a545c2411fa4b59c770eb5274d1b79b98c9a3f334962b